Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific TAXUS Liberte Stent ‘performs better than previous model’

Boston Scientific TAXUS Liberte Stent ‘performs better than previous model’

25th September 2009

Boston Scientific has revealed the results of a trial involving its new TAXUS Liberte Stent in comparison with the older TAXUS Express Stent.

The study found that the newer stent outperforms the first-generation example when it comes to small vessels and long coronary lesions.

Results from the three-year TAXUS ATLAS Small Vessel Trial showed a 55 per cent relative risk reduction in the rate of target lesion revascularisation in small vessels treated with the TAXUS Liberte Atom Stent as compared to its older counterpart.

Mark Turco, the co-principal investigator of the trial, said: “This data [?] suggests that these improvements are likely the result of the thinner struts and improved stent geometry of the TAXUS Liberte Stent.”

Another study into the firm’s equipment revealed this week that both the TAXUS Express and PROMUS models support the benefits of paclitaxel-eluting stents in diabetic patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.